Scholars@Duke
Christopher Hoimes

Christopher Hoimes

Instructor in the Department of Medicine
Medicine, Medical Oncology
905 S LaSalle St, DUMC 103861 ; Rm 2010, Durham, NC 27710

Scholarly Works - Other

Supplementary Table S3 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

Other · October 1, 2025 <p>Table S3 reports PFS for patients with anti–PD-1/PD-L1–naive melanoma who received nelitolimod 2 mg or 8 mg and pembrolizumab 200 mg (intention-to-treat).</p> ... Full text Cite

Supplementary Figure S1 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

Other · October 1, 2025 <p>Figure S1 shows the treatment schema with nelitolimod 2 mg or 8 mg and pembrolizumab 200 mg. Nelitolimod was administered weekly for 4 weeks, followed by one dose every 3 weeks for up to 22 doses.</p> ... Full text Cite

Supplementary Figure S2 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

Other · October 1, 2025 <p>Figure S2 shows detailed response and treatment duration data for patients with anti–PD-1/PD-L1–naive melanoma treated with nelitolimod 2 mg plus pembrolizumab 200 mg. The figure illustrated patterns of tumor response over time.</p>< ... Full text Cite

Supplementary Figure S6 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

Other · October 1, 2025 <p>Figure S6 shows transcriptomic data from paired tumor biopsies collected at baseline and on therapy from patients treated with nelitolimod 2 mg plus pembrolizumab 200 mg. The figure displays consistent and durable increases in the expressi ... Full text Cite

Supplementary Figure S3 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

Other · October 1, 2025 <p>Figure S3 shows best percentage changes from baseline in target lesion size, grouped by PD-L1 status, for patients treated with nelitolimod 8 mg plus pembrolizumab 200 mg. The plot highlights greater tumor shrinkage in patients with PD-L1– ... Full text Cite

Supplementary Figure S4 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

Other · October 1, 2025 <p>Figure S4 shows best percentage changes from baseline in target lesion size for patients treated with nelitolimod 2 mg or 8 mg plus pembrolizumab 200 mg. The plot illustrates the depth of tumor response across both dosing groups.</p> ... Full text Cite

Supplementary Figure S5 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

Other · October 1, 2025 <p>Figure S5 shows Kaplan-Meier curves depicting progression-free survival for patients treated with nelitolimod 2 mg or 8 mg in combination with pembrolizumab 200 mg. The figure illustrates time-to-event data for each dose group.</p> Full text Cite

Data from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

Other · October 1, 2025 <div>AbstractPurpose:<p>Nelitolimod (previously SD-101) is a toll-like receptor 9 agonist. We assessed whether intratumoral nelitolimod plus pembrolizumab potentiates antitumor activity in patients with advanced melanoma who had not pre ... Full text Cite

Data from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <div>Abstract<p>High-dose intravenous vitamin C (HDIVC) administered to produce pharmacologic concentrations shows promise in preclinical models and small clinical trials, but larger prospective randomized trials are lacking. We evaluat ... Full text Cite

Table S16 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <p>Table S16 shows Comparison of F2-Isoprostanes Control and Intervention Changes 60 minutes after Cycle 4</p> ... Full text Cite

Table S5 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <p>Table S5 shows AEs with Attribution Possible, Probable or Definite to Treatment (HDVIC or Placebo) listed by types and grades</p> ... Full text Cite

Table S7 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <p>Table S7 shows Serious Adverse Events (N = 11 patients), by Type and Grade. Attributions Assigned Docetaxel versus HDIVC or Placebo</p> ... Full text Cite

Table S2 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <p>Table S2 shows Association of HDIVC Treatment with PSA Response Adjusting for Prior Docetaxel Exposure</p> ... Full text Cite

Table S10 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <p>Table S10 shows ANCOVA Least-squares Means for Cycle 4, 6, and 8 FACT-P Total by Study Arm</p> ... Full text Cite

Table S4 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <p>Table S4 shows Adverse Events Included in the Co-primary Endpoint: Worst Grade by Patient</p> ... Full text Cite

Supplementary Methods from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <p>Supplementary methods include study design and participants, outcomes and statistical analysis, FACT-P questionnaire, pharmacokinetics, and F2-Isoprostanes</p> ... Full text Cite

Table S14 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <p>Table S14 shows Comparison of F2-Isoprostanes Control and Intervention Changes (post - pre) Immediately after Cycle 4</p> ... Full text Cite

Table S13 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <p>Table S13 shows Comparison of F2-Isoprostanes at Baseline between Treatment and Control Arms</p> ... Full text Cite

Table S15 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <p>Table S15 shows Comparison of F2-Isoprostanes Control and Intervention Changes (post - pre) Immediately after Cycle 6</p> ... Full text Cite

Table S12 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <p>Table S12 shows Comparison of FACT-P Change Scores Between Study Arms: Mean Difference Docetaxel + HDVIC Minus Docetaxel + Placebo</p> ... Full text Cite

Table S17 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <p>Table S17 shows Comparison of F2-Isoprostanes Control and Intervention Changes 60 minutes after Cycle 6</p> ... Full text Cite

Table S6 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <p>Table S6 shows AEs with Attribution Possible, Probable or Definite to Docetaxel listed by types and grades</p> ... Full text Cite

Table S1 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · March 26, 2025 <p>Table S1 shows Participating Sites and the Number of Patients Enrolled in the Trial at Each Institution</p> ... Full text Cite

Table S2 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S2 shows Association of HDIVC Treatment with PSA Response Adjusting for Prior Docetaxel Exposure</p> ... Full text Cite

Table S17 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S17 shows Comparison of F2-Isoprostanes Control and Intervention Changes 60 minutes after Cycle 6</p> ... Full text Cite

Table S5 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S5 shows AEs with Attribution Possible, Probable or Definite to Treatment (HDVIC or Placebo) listed by types and grades</p> ... Full text Cite

Table S6 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S6 shows AEs with Attribution Possible, Probable or Definite to Docetaxel listed by types and grades</p> ... Full text Cite

Table S12 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S12 shows Comparison of FACT-P Change Scores Between Study Arms: Mean Difference Docetaxel + HDVIC Minus Docetaxel + Placebo</p> ... Full text Cite

Table S14 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S14 shows Comparison of F2-Isoprostanes Control and Intervention Changes (post - pre) Immediately after Cycle 4</p> ... Full text Cite

Supplementary Methods from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Supplementary methods include study design and participants, outcomes and statistical analysis, FACT-P questionnaire, pharmacokinetics, and F2-Isoprostanes</p> ... Full text Cite

Table S16 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S16 shows Comparison of F2-Isoprostanes Control and Intervention Changes 60 minutes after Cycle 4</p> ... Full text Cite

Table S16 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S16 shows Comparison of F2-Isoprostanes Control and Intervention Changes 60 minutes after Cycle 4</p> ... Full text Cite

Table S7 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S7 shows Serious Adverse Events (N = 11 patients), by Type and Grade. Attributions Assigned Docetaxel versus HDIVC or Placebo</p> ... Full text Cite

Table S13 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S13 shows Comparison of F2-Isoprostanes at Baseline between Treatment and Control Arms</p> ... Full text Cite

Data from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <div>Abstract<p>High-dose intravenous vitamin C (HDIVC) administered to produce pharmacologic concentrations shows promise in preclinical models and small clinical trials, but larger prospective randomized trials are lacking. We evaluat ... Full text Cite

Table S15 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S15 shows Comparison of F2-Isoprostanes Control and Intervention Changes (post - pre) Immediately after Cycle 6</p> ... Full text Cite

Table S7 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S7 shows Serious Adverse Events (N = 11 patients), by Type and Grade. Attributions Assigned Docetaxel versus HDIVC or Placebo</p> ... Full text Cite

Table S10 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S10 shows ANCOVA Least-squares Means for Cycle 4, 6, and 8 FACT-P Total by Study Arm</p> ... Full text Cite

Supplementary Methods from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Supplementary methods include study design and participants, outcomes and statistical analysis, FACT-P questionnaire, pharmacokinetics, and F2-Isoprostanes</p> ... Full text Cite

Table S13 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S13 shows Comparison of F2-Isoprostanes at Baseline between Treatment and Control Arms</p> ... Full text Cite

Table S4 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S4 shows Adverse Events Included in the Co-primary Endpoint: Worst Grade by Patient</p> ... Full text Cite

Table S2 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S2 shows Association of HDIVC Treatment with PSA Response Adjusting for Prior Docetaxel Exposure</p> ... Full text Cite

Table S4 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S4 shows Adverse Events Included in the Co-primary Endpoint: Worst Grade by Patient</p> ... Full text Cite

Table S6 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S6 shows AEs with Attribution Possible, Probable or Definite to Docetaxel listed by types and grades</p> ... Full text Cite

Table S1 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S1 shows Participating Sites and the Number of Patients Enrolled in the Trial at Each Institution</p> ... Full text Cite

Table S12 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S12 shows Comparison of FACT-P Change Scores Between Study Arms: Mean Difference Docetaxel + HDVIC Minus Docetaxel + Placebo</p> ... Full text Cite

Table S15 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S15 shows Comparison of F2-Isoprostanes Control and Intervention Changes (post - pre) Immediately after Cycle 6</p> ... Full text Cite

Table S14 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S14 shows Comparison of F2-Isoprostanes Control and Intervention Changes (post - pre) Immediately after Cycle 4</p> ... Full text Cite

Table S10 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S10 shows ANCOVA Least-squares Means for Cycle 4, 6, and 8 FACT-P Total by Study Arm</p> ... Full text Cite

Table S5 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S5 shows AEs with Attribution Possible, Probable or Definite to Treatment (HDVIC or Placebo) listed by types and grades</p> ... Full text Cite

Table S17 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S17 shows Comparison of F2-Isoprostanes Control and Intervention Changes 60 minutes after Cycle 6</p> ... Full text Cite

Table S1 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · September 25, 2024 <p>Table S1 shows Participating Sites and the Number of Patients Enrolled in the Trial at Each Institution</p> ... Full text Cite

Supplementary Methods from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Supplementary methods include study design and participants, outcomes and statistical analysis, FACT-P questionnaire, pharmacokinetics, and F2-Isoprostanes</p> ... Full text Cite

Supplementary Methods from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Supplementary methods include study design and participants, outcomes and statistical analysis, FACT-P questionnaire, pharmacokinetics, and F2-Isoprostanes</p> ... Full text Cite

Figure 2 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Key secondary endpoints. Key secondary endpoints include rPFS, OS, duration of PSA response, and quality of life measured using the FACT-P instrument. <b>A,</b> rPFS and (<b>B</b>) OS are presented for docetaxel + H ... Full text Cite

Figure 1 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>CONSORT diagram. The diagram shows eligibility assessment, randomization, allocation, discontinuations, and numbers of subjects analyzed.</p> ... Full text Cite

Table S1 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S1 shows Participating Sites and the Number of Patients Enrolled in the Trial at Each Institution</p> ... Full text Cite

Table S17 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S17 shows Comparison of F2-Isoprostanes Control and Intervention Changes 60 minutes after Cycle 6</p> ... Full text Cite

Table S2 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S2 shows Association of HDIVC Treatment with PSA Response Adjusting for Prior Docetaxel Exposure</p> ... Full text Cite

Table S15 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S15 shows Comparison of F2-Isoprostanes Control and Intervention Changes (post - pre) Immediately after Cycle 6</p> ... Full text Cite

Table S16 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S16 shows Comparison of F2-Isoprostanes Control and Intervention Changes 60 minutes after Cycle 4</p> ... Full text Cite

Table S15 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S15 shows Comparison of F2-Isoprostanes Control and Intervention Changes (post - pre) Immediately after Cycle 6</p> ... Full text Cite

Table S14 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S14 shows Comparison of F2-Isoprostanes Control and Intervention Changes (post - pre) Immediately after Cycle 4</p> ... Full text Cite

Data from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <div>Abstract<p>High-dose intravenous vitamin C (HDIVC) administered to produce pharmacologic concentrations shows promise in preclinical models and small clinical trials, but larger prospective randomized trials are lacking. We evaluat ... Full text Cite

Table S16 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S16 shows Comparison of F2-Isoprostanes Control and Intervention Changes 60 minutes after Cycle 4</p> ... Full text Cite

Table S14 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S14 shows Comparison of F2-Isoprostanes Control and Intervention Changes (post - pre) Immediately after Cycle 4</p> ... Full text Cite

Table S1 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S1 shows Participating Sites and the Number of Patients Enrolled in the Trial at Each Institution</p> ... Full text Cite

Figure 2 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Key secondary endpoints. Key secondary endpoints include rPFS, OS, duration of PSA response, and quality of life measured using the FACT-P instrument. <b>A,</b> rPFS and (<b>B</b>) OS are presented for docetaxel + H ... Full text Cite

Table S17 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S17 shows Comparison of F2-Isoprostanes Control and Intervention Changes 60 minutes after Cycle 6</p> ... Full text Cite

Table S12 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S12 shows Comparison of FACT-P Change Scores Between Study Arms: Mean Difference Docetaxel + HDVIC Minus Docetaxel + Placebo</p> ... Full text Cite

Table S10 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S10 shows ANCOVA Least-squares Means for Cycle 4, 6, and 8 FACT-P Total by Study Arm</p> ... Full text Cite

Table S12 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S12 shows Comparison of FACT-P Change Scores Between Study Arms: Mean Difference Docetaxel + HDVIC Minus Docetaxel + Placebo</p> ... Full text Cite

Table S13 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S13 shows Comparison of F2-Isoprostanes at Baseline between Treatment and Control Arms</p> ... Full text Cite

Table S13 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S13 shows Comparison of F2-Isoprostanes at Baseline between Treatment and Control Arms</p> ... Full text Cite

Table S10 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S10 shows ANCOVA Least-squares Means for Cycle 4, 6, and 8 FACT-P Total by Study Arm</p> ... Full text Cite

Figure 1 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>CONSORT diagram. The diagram shows eligibility assessment, randomization, allocation, discontinuations, and numbers of subjects analyzed.</p> ... Full text Cite

Table S4 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S4 shows Adverse Events Included in the Co-primary Endpoint: Worst Grade by Patient</p> ... Full text Cite

Table S5 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S5 shows AEs with Attribution Possible, Probable or Definite to Treatment (HDVIC or Placebo) listed by types and grades</p> ... Full text Cite

Table S4 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S4 shows Adverse Events Included in the Co-primary Endpoint: Worst Grade by Patient</p> ... Full text Cite

Table S7 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S7 shows Serious Adverse Events (N = 11 patients), by Type and Grade. Attributions Assigned Docetaxel versus HDIVC or Placebo</p> ... Full text Cite

Table S5 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S5 shows AEs with Attribution Possible, Probable or Definite to Treatment (HDVIC or Placebo) listed by types and grades</p> ... Full text Cite

Table S2 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S2 shows Association of HDIVC Treatment with PSA Response Adjusting for Prior Docetaxel Exposure</p> ... Full text Cite

Table S6 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S6 shows AEs with Attribution Possible, Probable or Definite to Docetaxel listed by types and grades</p> ... Full text Cite

Table S6 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S6 shows AEs with Attribution Possible, Probable or Definite to Docetaxel listed by types and grades</p> ... Full text Cite

Table S7 from High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Other · August 20, 2024 <p>Table S7 shows Serious Adverse Events (N = 11 patients), by Type and Grade. Attributions Assigned Docetaxel versus HDIVC or Placebo</p> ... Full text Cite

Data from Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNβ-Driven Antitumor Immunity

Other · March 31, 2023 <div>Abstract<p>Effective cancer immunotherapy depends on the robust activation of tumor-specific antigen-presenting cells (APC). Immune agonists encapsulated within nanoparticles (NP) can be delivered to tumor sites to generate powerfu ... Full text Cite

Supplementary Data from Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNβ-Driven Antitumor Immunity

Other · March 31, 2023 <p>SF1: IFNβ production from macrophages by ELISA analysis; SF2: FMT imaging of mammary tumors ex vivo for spatial localization of nanoparticle; SF3: Confocal micrographs of DiI-nanoparticle fluorescence in mammary tumor tissue; SF4: Represen ... Full text Cite

Supplementary Data from Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNβ-Driven Antitumor Immunity

Other · March 31, 2023 <p>SF1: IFNβ production from macrophages by ELISA analysis; SF2: FMT imaging of mammary tumors ex vivo for spatial localization of nanoparticle; SF3: Confocal micrographs of DiI-nanoparticle fluorescence in mammary tumor tissue; SF4: Represen ... Full text Cite

Data from Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNβ-Driven Antitumor Immunity

Other · March 31, 2023 <div>Abstract<p>Effective cancer immunotherapy depends on the robust activation of tumor-specific antigen-presenting cells (APC). Immune agonists encapsulated within nanoparticles (NP) can be delivered to tumor sites to generate powerfu ... Full text Cite